News

 

Nerviano Medical Sciences Appointed Gergely Balint MSc to Accelerate MPS1 Inhibitor Asset Development

Nerviano Medical Sciences Appointed Gergely Balint MSc to Accelerate MPS1 Inhibitor Asset Development

01 February 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Gergely Balint, MSc, has joined the Global Asset Leadership Team to lead the development and maximize the value of its MPS1 Inhibitor Asset, NMS-01940153E (NMS-153).
(Click the title for the complete article)

Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset – Terrence West, MBA, joins as New Business, Virtual CEO

Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset – Terrence West, MBA, joins as New Business, Virtual CEO

January 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the senior appointment to drive validation and maximize the value of its IDH1/IDH2 Inhibitor Asset, NMS-173, and facilitate its expanding and advancing clinical pipeline. Terrence West, MBA, joins as New Business, Virtual CEO.
(Click the title for the complete article)

MPS1 (NMS-01940153E) Kinase Inhibitor Shows Clinical Activity in Primary Liver Cancer

MPS1 (NMS-01940153E) Kinase Inhibitor Shows Clinical Activity in Primary Liver Cancer

MPS1 Kinase Inhibitor Shows Clinical Activity in Primary Liver Cancer

The targeted drug NMS-01940153E, a monopolar spindle 1 (MPS1) kinase inhibitor, has shown signs of clinical activity in a Phase I study of patients with relapsed or refractory unresectable hepatocellular carcinoma (HCC). The study findings were reported at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
(Click the title for the complete article)

NMS Group S.p.A. names Sidney Shin-Yi Dung as Chief Operating Officer to drive growth

NMS Group S.p.A. names Sidney Shin-Yi Dung as Chief Operating Officer to drive growth

NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces the appointment of Ms. Sidney Dung as Chief Operating Officer with immediate effect. Ms. Dung, currently a member of the Company’s Executive Leadership Team and Chief of Staff, will take primary responsibility for accelerating groupwise operational performance, continuing the transformation of the business model of each subsidiary and implementing the strategic vision and values of the company, in collaboration with leaders across the firm in her new role as COO.
(Click the title for the complete article)

NMS-01940153E (NMS-153) at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

NMS-01940153E (NMS-153) at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

A week from the presentation of Nerviano Medical Sciences S.r.l. (a member of NMS Group) on NMS-01940153E (NMS-153) at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, we’re thrilled to share the official press release from ENA 2022 of NMS-153. A highly potent and selective inhibitor of the MPS1 kinase, NMS-153 is a mitotic regulator frequently overexpressed and activated in cancer. NMS-153 showed a broad preclinical activity in different tumor types, including HCC. Please read the press release here! 
(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. names Salvatore Marengoni Galdy, M.D., Global Clinical Lead

Nerviano Medical Sciences S.r.l. names Salvatore Marengoni Galdy, M.D., Global Clinical Lead

NMS today announced that Salvatore Marengoni Galdy, M.D., has joined the Global Clinical Development Team as Global Clinical Lead, effective immediately. Dr. Galdy will drive values of our assets through planning and leading the clinical development to meet all time, quality, budget, Company standards and scientific requirements.
(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. Shared Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 

Nerviano Medical Sciences S.r.l. Shared Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 

Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today shared data from the Company’s Phase I/II clinical study of NMS-01940153E in Hepatocellular carcinoma (HCC) in an oral presentation by Dr. Maria Reig at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics  (ENA 2022)  in Barcelona.
(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. Announces a Poster Presentation on NMS-03602173 at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Nerviano Medical Sciences S.r.l. Announces a Poster Presentation on NMS-03602173 at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that preclinical data from the Company’s asset NMS-03602173 will be reported in a poster presentation by Dr. Paola Magnaghi at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics  (ENA 2022)  which will be held October 26-28, 2022 at the CCIB in Barcelona.
(Click the title for the complete article)

NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR

NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR

NERVIANO, 18 October 2022 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the Company’s Phase I/II clinical study of NMS-01940153E in Hepatocellular carcinoma (HCC) will be reported in an oral presentation by Dr. Maria Reig at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics  (ENA 2022)  which will be held October 26-28, 2022 at the CCIB in Barcelona.
(Click the title for the complete article)

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO